We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00214838
Recruitment Status : Unknown
Verified December 2006 by Callisto Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : September 22, 2005
Last Update Posted : December 5, 2006
Sponsor:
Information provided by:

Study Description
Brief Summary:
The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: Atiprimod Phase 1 Phase 2

Detailed Description:

The primary objectives of this study are to identify the maximum tolerated dose(MTD) and to evaluate safety of atiprimod in patients with advanced cancer.

The secondary objectives of this study are 1) to measure the pharmacokinetics of atiprimod and 2) to evaluate the efficacy of atiprimod treatment in patients with advanced cancers and 3) to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 61 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
Study Start Date : March 2005
Estimated Study Completion Date : March 2007
Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. The primary objectives of this study are to identify the maximum tolerated dose
  2. MTD) and to evaluate the safety of atiprimod when given in doses starting at
  3. 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in
  4. patients with advanced cancer.

Secondary Outcome Measures :
  1. The secondary objectives of this study are to measure the pharmacokinetics of
  2. atiprimod, to evaluate the efficacy of atiprimod treatment in patients with
  3. advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and
  4. capsules at the starting dose, with the intent of switching to capsules for
  5. the dose escalation if the capsules pose no safety issues.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histological proof of advanced cancer and must have failed or relapsed following standard therapy or have no standard therapy available.
  • estimated life expectancy of at least 12 weeks.
  • must have evaluable disease.
  • ECOG(Zubrod) PS of 0 to 2
  • sign informed consent.
  • age 13 years or more at time of signing informed consent.

Exclusion Criteria:

  • renal insufficiency
  • concomitant radiotherapy, chemotherapy or other investigational therapies.
  • peripheral neuropathy grade 3 or greater (NCI CTC version 3 grading)
  • evidence of clinically significant mucosal or internal bleeding
  • any condition that in the opinion of the investigator, places the patient at unacceptable risk if he/she were to participate in the study.
  • clinically relevant active infection or serious co-morbid medical conditions.
  • as atiprimod is a potent inhibitor of CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics will be excluded.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214838


Locations
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Callisto Pharmaceuticals
Investigators
Study Director: Donald Picker, PhD Callisto Pharmaceuticals Inc
More Information

ClinicalTrials.gov Identifier: NCT00214838     History of Changes
Other Study ID Numbers: CP-102
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: December 5, 2006
Last Verified: December 2006

Keywords provided by Callisto Pharmaceuticals:
cancer, atiprimod

Additional relevant MeSH terms:
Neoplasms